

1. Use of tasimelteon in the manufacture of a medicament for the treatment of one or more symptoms of a circadian rhythm sleep disorder in a patient that has a cryptochrome circadian clock 1 (CRY1) genotype associated with said disorder, wherein the CRY1 genotype associated with said disorder is selected from a group consisting of: genotypes that include at least one copy of the rs184039278 allele and genotypes that include at least one copy of the rs780614131 allele.

~~2. The use of claim 1, wherein the CRY1 genotype associated with said disorder includes at least one copy of the rs184039278 allele.~~

~~3. The use of claim 1, wherein the CRY1 genotype associated with said disorder includes at least one copy of the rs780614131 allele.~~

~~4. The use of claim 1, wherein the CRY1 genotype is a loss of function (LOF) genotype.~~

52. The use of claim 1, wherein said disorder is delayed sleep wake phase disorder (DSWPD).

~~63.~~ The use of claim 1, wherein the medicament includes 20 mg of tasimelteon.

74. The use of claim 1, wherein the treatment of said disorder includes improving at least one sleep parameter selected from a group consisting of: latency to persistent sleep (LPS); sleep efficiency (%) during the first, second, and/or final thirds of the night; rapid eye movement (REM) sleep duration; total sleep time (TST), including during the first two-thirds of the night; and wake after persistent sleep (WASO).

~~85.~~ Use of tasimelteon in the manufacture of a medicament for improving one or more sleep parameters in an individual determined to possess a variant of the cryptochrome circadian clock 1 (CRY1) genotype associated with a circadian rhythm sleep disorder (CRSD),

wherein said medicament is for administration to said individual daily, at a time proximately before the individual's established bedtime, to improve one or more sleep parameters in said individual,

wherein the variant of the CRY1 genotype associated with the CRSD is selected from a group consisting of: the rs184039278 allele and the rs780614131 allele.

~~9. The use of claim 8, wherein the variant of the CRY1 genotype associated with a CRSD is the rs184039278 allele.~~

~~10. The use of claim 8, wherein the variant of the CRY1 genotype associated with the CRSD includes the rs780614131 allele.~~

~~11. The use of claim 8, wherein the variant of the CRY1 genotype associated with the CRSD is a loss of function (LOF) genotype.~~

~~126.~~ The use of claim ~~85~~, wherein the CRSD is delayed sleep wake phase disorder (DSWPD).

~~137.~~ The use of claim ~~85~~, wherein the medicament includes 20 mg of tasimelteon.

~~148.~~ The use of claim ~~85~~, wherein improving sleep includes improving at least one sleep parameter selected from a group consisting of: latency to persistent sleep (LPS); sleep efficiency (%) during the first, second, and/or final thirds of the night; rapid eye movement (REM) sleep duration; total sleep time (TST), including during the first two-thirds of the night; and wake after persistent sleep (WASO).

~~159.~~ Use of tasimelteon in the manufacture of a medicament treating one or more symptoms of a circadian rhythm sleep disorder in a patient who has a period 1 (PER1) genotype that includes at least one copy of the rs112474322 allele and is associated with said disorder.

~~16. The use of claim 15, wherein the PER1 genotype associated with said disorder includes at least one copy of the rs112474322 allele.~~

~~17. The use of claim 15, wherein the PER1 genotype associated with said disorder is a loss of function (LOF) genotype.~~

~~1810.~~ The use of claim ~~159~~, wherein said disorder is delayed sleep wake phase disorder (DSWPD).

~~1911.~~ The use of claim ~~159~~, wherein the medicament includes 20 mg of tasimelteon.

~~20~~12. The use of claim ~~15~~9, wherein treating said disorder includes improving at least one sleep parameter selected from a group consisting of: latency to persistent sleep (LPS); sleep efficiency (%) during the first, second, and/or final thirds of the night; rapid eye movement (REM) sleep duration; total sleep time (TST), including during the first two-thirds of the night; and wake after persistent sleep (WASO).

~~21~~13. Use of tasimelteon in the manufacture of a medicament for improving one or more sleep parameters in an individual possessing a variant of the period 1 (PER1) genotype that includes the rs112474322 allele and is associated with a circadian rhythm sleep disorder (CRSD),

wherein the medicament is for administration to said individual daily, at a time proximately before the individual's established bedtime, to improve one or more sleep parameters in said individual.

~~22. The use of claim 21, wherein the variant of the PER1 genotype associated with the CRSD includes the rs112474322 allele.~~

~~23. The use of claim 21, wherein the variant of the PER1 genotype associated with the CRSD is a loss of function (LOF) genotype.~~

~~24~~14. The use of claim ~~21~~13, wherein the CRSD is delayed sleep wake phase disorder (DSWPD).

~~25~~15. The use of claim ~~21~~13, wherein the medicament includes 20 mg of tasimelteon.

~~26~~16. The use of claim ~~21~~13, wherein improving sleep includes improving at least one sleep parameter selected from a group consisting of: latency to persistent sleep (LPS); sleep efficiency (%) during the first, second, and/or final thirds of the night; rapid eye movement (REM) sleep duration; total sleep time (TST), including during the first two-thirds of the night; and wake after persistent sleep (WASO).